LeMaitre Vascular, Inc. (LMAT) To Go Ex-Dividend on November 20th

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced a quarterly dividend on Monday, October 27th. Investors of record on Thursday, November 20th will be given a dividend of 0.20 per share by the medical instruments supplier on Thursday, December 4th. This represents a c) dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, November 20th.

LeMaitre Vascular has increased its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 14 consecutive years. LeMaitre Vascular has a dividend payout ratio of 33.6% meaning its dividend is sufficiently covered by earnings. Analysts expect LeMaitre Vascular to earn $2.17 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 36.9%.

LeMaitre Vascular Trading Down 1.6%

NASDAQ:LMAT opened at $86.99 on Tuesday. The stock’s fifty day moving average price is $88.71 and its two-hundred day moving average price is $86.89. The company has a market cap of $1.97 billion, a P/E ratio of 42.23, a P/E/G ratio of 2.29 and a beta of 0.77. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. LeMaitre Vascular has a 1 year low of $71.42 and a 1 year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.05. The company had revenue of $61.05 million during the quarter, compared to analyst estimates of $62.18 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the company earned $0.49 earnings per share. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. As a group, analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LMAT. Victory Capital Management Inc. grew its holdings in LeMaitre Vascular by 45.9% during the 1st quarter. Victory Capital Management Inc. now owns 79,871 shares of the medical instruments supplier’s stock valued at $6,701,000 after buying an additional 25,133 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of LeMaitre Vascular during the 1st quarter worth approximately $728,000. Avantax Advisory Services Inc. boosted its position in shares of LeMaitre Vascular by 1.5% during the 1st quarter. Avantax Advisory Services Inc. now owns 15,035 shares of the medical instruments supplier’s stock valued at $1,261,000 after acquiring an additional 229 shares during the last quarter. Cetera Investment Advisers grew its holdings in shares of LeMaitre Vascular by 209.6% in the first quarter. Cetera Investment Advisers now owns 8,522 shares of the medical instruments supplier’s stock valued at $715,000 after purchasing an additional 5,769 shares in the last quarter. Finally, Federated Hermes Inc. increased its position in LeMaitre Vascular by 1.3% in the first quarter. Federated Hermes Inc. now owns 39,504 shares of the medical instruments supplier’s stock worth $3,314,000 after purchasing an additional 518 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.